Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9200 posts found.

Roche shares data from phase 3 trial of Xolair as allergy treatment

February 26, 2024 Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy

Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …
News

Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

February 26, 2024 Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …
News

AbbVie and Tentarix collaborate on oncology and immunology treatments

February 23, 2024 Research and Development AbbVie, Oncology, collaboration, immunology

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …
News

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

February 23, 2024 Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …
News

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

February 21, 2024 Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
News

Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment

February 21, 2024 Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical

Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
News

Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics

February 16, 2024 Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
News

Freenome raises $254m funding for early cancer detection platform

February 16, 2024 Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …
News

BioNTech and Autolus announce CAR T-cell therapy collaboration

February 9, 2024 Research and Development Autolus, BioNTech, CAR T-cell, Oncology, collaboration

BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR …
News

Regenxbio announces positive data from trial for MPS II treatment

February 8, 2024 Research and Development Hunter syndrome, MPS II, Neurology, Regenxbio, clinical trial

Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …
News

Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment

February 8, 2024 Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension

Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …
News

Medidata and Sanofi Vaccines extend collaboration

February 7, 2024 Research and Development Immunology, Medidata, Sanofi Vaccines, eCOA

Medidata and Sanofi Vaccines have announced a collaboration utilising Medidata electronic clinical outcome assessment (eCOA) within vaccine trials, building on …
News

Vertex announces positive results from trial for cystic fibrosis combination treatment

February 6, 2024 Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis

Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …
News
milad-fakurian-58z17lnvs4u-unsplash_2

Vivet Therapeutics gains €4.9m for gene therapy development

February 2, 2024 Research and Development CTX, Neurology, Vivet Therapeutics, funding, gene therapy

Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a …
News

AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM

February 2, 2024 Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial

AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024